JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing discontinuation of imvotamab development alongside a pause of its clinical stage IgM assets, it sees its Underweight thesis “now borne out.” Given the uncertain path forward for IGM, JPMorgan no longer ascribes pipeline value in its updated model for shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences Halts Antibody Therapies, Cuts Workforce
- IGM Biosciences downgraded to Hold from Buy at Jefferies
- AMD downgraded, Nike upgraded: Wall Street’s top analyst calls
- IGM Biosciences price target lowered to $2 from $12 at Truist
- Morning Movers: Constellation Energy climbs following deal to buy Calpine